Long-term study of oral levosimendan for heart failure
Treatments studied
Part of Heart & circulation clinical trials.
This long-term study gives continued access to the oral levosimendan medication for people who finished the earlier TNX-103 study. The goal is to see if ongoing treatment remains safe and helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the earlier TNX-103 study.
- Your doctor must agree that continuing this treatment could help you.
- You cannot have severe liver problems (like cirrhosis or active hepatitis B or C).
- Your kidney function must be good enough (eGFR above 30).
- If you are a woman able to have children, you must use effective contraception and not be pregnant or breastfeeding.
- If you are a man, you must agree to not donate sperm during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug for people with a type of heart failure where the heart pumps normally but is stiff. The goal is to see if the drug can improve symptoms and quality of life.
This trial tests a medicine called levosimendan to see if it helps people with severe heart failure who still feel breathless at rest despite standard treatment. It may improve heart function and reduce symptoms.
This study tests an experimental drug called LY3971297 to see if it can help people with chronic heart failure. It aims to find out if the drug is safe and if it improves heart function.
This trial tests an investigational drug given as an injection under the skin for people with a type of hypertrophic cardiomyopathy that does not block blood flow out of the heart. The goal is to see if the drug is safe and may help improve symptoms.
This Phase 3 study continues treatment for people with pulmonary hypertension who finished an earlier parent study and have no other approved treatment option. It tests whether continuing their current medicine can help them keep getting benefit and stay safe.
This study is for people who have completed an earlier clinical trial for pulmonary fibrosis. It checks the long-term safety and tolerability of the study drug.
Hear when a new Pulmonary Hypertension Associated With HFpEF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.